ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3
RGD ID:
1304938
Description:
Predicted to enable GTPase activator activity; phosphatidylinositol-3,4,5-trisphosphate binding activity; and phosphatidylinositol-3,4-bisphosphate binding activity. Predicted to be involved in signal transduction. Predicted to act upstream of or within negative regulation of cell migration; negative regulation of small GTPase mediated signal transduction; and regulation of cell shape. Predicted to be located in lamellipodium and ruffle. Predicted to be active in cytoplasm. Orthologous to human ARAP3 (ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3); PARTICIPATES IN phosphatidylinositol 3-kinase class I signaling pathway; INTERACTS WITH 1,3-dinitrobenzene; amphetamine; atrazine.
Arap3-ps1; arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3; ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3, pseudogene 1; centaurin, delta 3; Centd3; dual-specificity Rho- and Arf-GTPase activating protein 1; LOC361314; RGD1304938; similar to ARF-GAP, RHO-GAP, ankyrin repeat and pleckstrin homology domains-containing protein 3
[[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARAP3 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARAP3 mRNA
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARAP3 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARAP3 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARAP3 mRNA
similar to ARF-GAP, RHO-GAP, ankyrin repeat and pleckstrin homology domains-containing protein 3; dual-specificity Rho- and Arf-GTPase activating protein 1 (predicted)
similar to ARF-GAP, RHO-GAP, ankyrin repeat and pleckstrin homology domains-containing protein 3; dual-specificity Rho- and Arf-GTPase activating protein 1 (predicted)
similar to ARF-GAP, RHO-GAP, ankyrin repeat and pleckstrin homology domains-containing protein 3; dual-specificity Rho- and Arf-GTPase activating protein 1 (predicted)